key: cord-0768325-c2uj0z7d authors: Chen, Chaojin; He, Yufeng; Feng, Yawei; Hong, Weilong; Luo, Gangjian; Ye, Zhiqiang title: Long non-coding RNA review and implications in acute lung inflammation date: 2021-01-15 journal: Life Sci DOI: 10.1016/j.lfs.2021.119044 sha: 90570a0d12443ae19bccad146dc182e93857d141 doc_id: 768325 cord_uid: c2uj0z7d Acute lung inflammatory diseases severely affect the patients' recovery and outcomes worldwide. Unregulated acute inflammatory response is fundamentally central to acute lung inflammation including acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). To limit the potentially deleterious effects of acute lung inflammation, complex transcriptional and posttranscriptional regulatory networks have been explored, which often involves long noncoding RNAs (lncRNA). LncRNAs are RNAs that longer than 200 nucleotides, functioning as scaffolds or decoys in the cytoplasm or nucleus. By now, lncRNAs have been found to join in all major cellular processes including cell proliferation, metabolism, stress response or death. Extensive advance over the last decade furthermore indicated a fundamental role of lncRNAs in acute lung inflammation. This article reviews and summarizes the current knowledge on lncRNA in acute lung inflammatory response. Being one of main target organs of pro-inflammatory mediators released and secreted globally during trauma, sepsis, and major surgery, the lung was at high risk of acute lung inflammatory diseases. The unregulated acute inflammatory response would cause acute lung injury (ALI) and its severe form, known as acute respiratory distress syndrome (ARDS), which lead to high morbidity and mortality [1] . Acute lung inflammation was characterised fundamentally by dysfunction of the barrier properties of the pulmonary epithelium and endothelium due to direct pulmonary insults as well as indirect systemic inflammatory responses. Although a variety of anti-inflammation pharmacotherapy have been applied, the morbidity and outcome of ALI/ARDS patients were still poor. It is of particular importance to explore the new mechanism of acute lung inflammation for early diagnosis and treatment. To limit the potentially deleterious effects of acute lung inflammation, complex transcriptional and posttranscriptional regulatory networks have been explored, which often involves long noncoding RNAs (lncRNA). LncRNAs, regarded as transcripts exceed 200 nucleotides with little low coding potential, was considered as the waste of biological metabolism in the past. But in recent decades, lncRNAs were found to involve in diverse biological processes, such as cell differentiation, proliferation, apoptosis, pyroptosis, and participates in various stress responses [2] . It was reported that lncRNAs might regulate gene expression by several different ways, including binding to microRNAs, mRNAs or proteins via the regulation of epigenetic modifications, transcriptional and posttranscriptional processing [3] . At present, lncRNAs have been found abnormally expressed in many inflammatory and infectious diseases. It was reported that lncRNAs might regulate the expression of researches showed that lncRNAs also own encoding ability. For example, lncRNA 00961 was found to encode SPAR and negatively regulate mTORC1 during muscle regeneration [12] . Ruiz-Orera also identified several lncRNAs which could translate RNA into proteins [3] . Researchers have conducted large numbers of extensive and in-depth explorations to clarify the mechanism of lncRNAs in different diseases comprehensively. LncRNAs were found to regulate genes at three levels including the epigenetic, transcriptional and posttranscriptional levels. 1) epigenetic level: mainly including chromatin modification, genomic imprinting and dosage compensation [13, 14] . 2) transcriptional level: binding with target proteins in cis-acting elements or in a complexes form [15] [18] . The special mechanism of ceRNAs indicated that non-coding and coding RNAs could interact via competing for miRNA binding, thus reciprocally affecting their respective expression levels. As time goes on, more adcances in the regulating mechanisms of lncRNAs will be reported in the near future to help us understanding its entire regulation network. Acute lung inflammation is one of the main features in the pathogenesis of many acute lung diseases, such as ALI, ARDS and so on. Irrespective of the initial cause, ALI/ARDS is fundamentally characterized by severe inflammatory responses, intense epithelial/endothelial barrier damage, as well as alveolar edema [19] . Although there are some effective strategies to alleviate acute lung inflammation, the outcome of patients with acute lung inflammation has not yet improved and the underlying mechanism has not yet been clarified [16] . Multiple pulmonary cells are involved in acute lung inflammation, including epithelial cells, labrocyte, macrophages, neutrophils, mononuclear cells and T cells [20, 21] . Since that alveolar macrophages (AMs) play central roles in both the initiation and resolution of acute inflammatory responses, we have focused on its underlying mechanisms in acute lung inflammation. Different from classic macrophages, AMs are derived from yoke-sac procurers in fetal monocytes and comprise the majority of inflammatory cells in the lung [22] . With inflammatory invasions, bone marrow derived monocytes are recruited to the bronchoalveolar space and diff erentiated into AMs [23] to form the first-line host defense against infection, acting as antigen-presenting cells and releasing pro-inflammatory cytokines to propagate the inflammatory responses in ALI/ARDS [24] . The functional phenotype of AMs is modulated by different microenvironment of the lung [19] , which mainly including two distinct subsets: classically activated M1 macrophages (M1) and alternatively activated M2 macrophages (M2). Accumulating evidence showed that in the early stage of acute lung inflammation, large amounts of M1 secrete molecules IL-6, TNF-α, and IL-1 to propagate inflammatory responses and mediate host defense against various bacteria or viruses, while M2 secrete biological mediators TGF-β, IL-10, and chemokines engaged in infection, immune-regulation and tissue reconstruction [25] . Notably, M2 has four subtypes (M2a, M2b, M2c, and M2d) and the regulatory macrophages (M2b) produce a lot of anti-inflammatory cytokine, such as IL-10, to control the excessive inflammations and auto-immune reactions [26] . The bacterial or viral lung inflammation [29] . For instance, a CD169 + IMs subset substantially located to the bronchovascular tree was recently reported to regulate lung inflammation via regulating production of inflammatory cytokines and innate immune cell infiltration [30] . Moreover, inducing metabolic and epi-genetic reprogramming of lung IMs toward an anti-inflammatory phenotype could reduce inflammatory lung injury [31] and protect from airway allergic inflammation [32] . Although our understanding of the IMs' spatial and anatomical positioning and functions is still limited, emerging evidence suggests that they play vital roles in maintaining immune and tissue homeostasis in lung inflammation [33, 34] . Multiple types of cell injury and programmed cell death were also found in acute lung inflammation, mainly includes cellular apoptosis, pyroptosis, autophagy, necrosis. Among which pyroptosis is a newly discovered type of programmed cell death. study also showed that Ang1 exerted beneficial role of phosgene-induced ALI through inhibiting NLRP3 inflammasome activation and pyroptosis [37] . Conventional research on acute lung inflammation often involved investigations on gene expression, specific protein or protein related signaling pathways, etc. The discovery of lncRNA reveals a new insight on the pathogenesis of acute lung inflammation, which will open a new era for researchers to develop specific effective therapeutics. Several lncRNAs have been identified being involved in the procedure of acute lung inflammation, through modulating miRNAs or downstream targets or directly regulate pyroptosis [38, 39] . We concluded the regulation of reported LncRNAs in acute lung inflammation as shown in Table 1 . Metastasis associated lung adenocarcinoma transcript1(MALAT1), a lncRNA located in more than 40 kb away on mice chromosome 19 from Neat1, is reported essential in the regulation of acute lung inflammation, especially in septic-lung injury [6] . For example, MALAT1 activates p38 MAPK/p65 NF-κB signaling pathway to evoke and intensify inflammation in septic-lung injury model [40] . Dai L et al reported that MALAT1 was a potential biomarker to predict elevated ARDS risk and correlate with severe disease condition and raised mortality in sepsis patients [6] . , which also provided a potential target for acute lung inflammation. Kölling M and his colleague also reported that MALAT1 knockdown could ameliorate histopathologic changes in lung injury in hypoxia-induced pulmonary hypertension [45] . All the increasing studies confirmed that MALAT1 knockdown might be potential therapeutic way to alleviate acute lung inflammation[7]. Recently, lncRNA nuclear paraspeckle assembly transcript 1 (NEAT1) has grown up to be a topic of concern due to its pleiotropic function in inflammation-related diseases. It has been indicated there was positive correlation between high levels of Hongchao Zhou and his colleague confirmed that NEAT1 may modulate alveolar epithelial cells (AECs) pyroptosis and reduce inflammatory response to against ALI-induced ALI/ARDS by suppressing HMGB1/RAGE-NF-κB signaling [48] . Furthermore, NEAT1 inhibition alleviates cell apoptosis and promotes proliferation in sepsis-induced ALI. All the studies provide a theoretical basis for the therapy of NEAT1 in acute lung inflammation. Increasing studies confirmed that lncRNAs can act as miRNA decoys to sequestrate the miRNAs and thus favors expression of their repressed target mRNAs in acute lung inflammation. For instance, cancer susceptibility candidate 2 (CASC2), which is a lncRNA downregulated in multiple cancer types, was recently found acting as a competitive endogenous RNA that regulates AQP1 expression by sponging to miR-144-3p to protect lung epithelial cell from apoptosis in acute lung injury [49] . Besides CASC2, down-regulation of cancer susceptibility candidate 9 (CASC9) was also reported to regulate miR-195-5p/PDK4 axis and exacerbate ALI in sepsis [50] . Likewise, growth arrest special 5 (GAS5) also acted as a competitive endogenous RNA to promote DUSP1 expression via sponging miR-429 to suppresses inflammation and alveolar epithelial cell apoptosis [51] . Another study showed that binding to miR-138 [63] . Many new lncRNAs have been identified to be biomarkers for clinical outcomes of ARDS/ALI. Recent evidence showed that lncRNA THRIL was upregulated in patients with ARDS [47] and it was recommended as biomarker that positively correlated with mortality in sepsis-induced ARDS patients [64] . While plasma Lnc-IL7R was significantly downregulated in ARDS patients [65] , and it has been verified to negatively regulate IL7R expression to inhibit LPS-induced acute lung inflammation [66] . LncRNA A_30_P01029194 and A_30_P01029806 might also serve as candidate biomarkers in ALI [67] . Another genome-wide transcriptome analysis revealed that lncRNA NONMMUT065867, NONMMUT064312 and NONMMUT018123 were closely related to the elevated NLRP3 expression and ARDS [68] . LncRNAs have served as promising targets for acute lung inflammation by regulating miRNAs, targets or proteins, and many studies performed in LPS-induced ALI models have revealed the potential targeting lncRNAs to regulate acute lung inflammation, which provided a strong therapeutic basis for acute lung inflammation. Moreover, lncRNAs were also reported to play important roles in mesenchymal stem J o u r n a l P r e -p r o o f cells (MSCs) and MSC-derived exosomes treatment of acute lung inflammation [69] [70] [71] . However, researchers have not obtained sufficient evidence to confirm the therapeutic effects of these treatments on acute lung inflammation in clinical trials. For instance, plasma lnc-IL7R was preliminarily suggested as a biomarker in ARDS patients [72] , but the sample size was small that still needs further confirmation. In addition, although numerous clinical trials of MSCs transplantation for ARDS including COVID-19 ARDS treatment have been registered and reported [73] [74] [75] , whether lncRNAs are involved in the treatment still need further exploration. Moreover, before targeting the lncRNAs therapy for actue lung inflammation, several crucial challenges persist and need to be addressed. Firstly, since lncRNAs are poorly conserved among different species, it is difficult to confirm role of the selected lncRNAs in patients with acute lung inflammation in animal models, thus limits the exploration of the mechanism of lncRNAs in regulating actue lung inflammation [76] . Secondly, most current studies have focused on the role of lncRNAs as ceRNA. However, expression of most lncRNAs is generally not high in cells, in contrast to highly expressed miRNAs. It is difficult to coordinate the sponge function of ceRNAs because miRNAs offer only 1 binding site per lncRNA. Acute lung inflammation including ALI/ARDS still lacks specific therapeutic targets. More and more lncRNAs have been found to play important roles in pathogenesis of ALI/ARDS and may serve as new diagnostic and treatment biomarkers for ALI/ARDS. Increasing evidence shows that lncRNAs can bind to microRNAs, mRNAs or proteins to regulate epigenetic modifications, transcriptional and posttranscriptional processing in epithelial cells, AMs, neutrophils and so on, which provides potential therapeutic targets for ALI/ARDS and basis for drug therapy. However, the underlying mechanisms and therapeutic potential of lncRNAs in acute lung inflammation still need further investigation and confirmation in the future. THRIL Sepsis alveolar epithelial cells as biomarkers [64] IL7R ARDS alveolar epithelial cell as biomarkers [65] J o u r n a l P r e -p r o o f Dihydromyricetin Alleviates Sepsis-Induced Acute Lung Injury through Inhibiting NLRP3 Inflammasome-Dependent Pyroptosis in Mice Model History, Discovery, and Classification of lncRNAs Long non-coding RNAs as a source of new peptides The research progress of LncRNA involved in the regulation of inflammatory diseases ncRNAs in Inflammatory and Infectious Diseases Long noncoding RNA Malat1 regulates differential activation of macrophages and response to lung injury The product of the H19 gene may function as an RNA GENCODE reference annotation for the human and mouse genomes NONCODEV5: a comprehensive annotation database for long non-coding RNAs Long noncoding RNAs in cardiovascular diseases mTORC1 and muscle regeneration are regulated by the LINC00961-encoded SPAR polypeptide Drosophila dosage compensation: a complex voyage to the X chromosome CTCF maintains differential methylation at the Igf2/H19 locus The interaction of lncRNA EZR-AS1 with SMYD3 maintains overexpression of EZR in ESCC cells Mammalian Staufen1 recruits Upf1 to specific mRNA 3'UTRs so as to elicit mRNA decay Extracellular Vesicle: An Emerging Mediator of Intercellular Crosstalk in Lung Inflammation and Injury Acute respiratory distress in adults Past and Present ARDS Mortality Rates: A Systematic Review Macrophages: Their role, activation and polarization in pulmonary diseases Developmental origin of lung macrophage diversity. Development Alveolar macrophage depletion is associated with increased surfactant pool sizes in adult rats Macrophage heterogeneity in 28 Three Unique Interstitial Macrophages in the Murine Lung at Steady State Alveolar macrophages: plasticity in a tissue-specific context Identification of a nerve-associated, lung-resident interstitial macrophage subset with distinct localization and immunoregulatory properties The angiocrine Rspondin3 instructs interstitial macrophage transition via metabolic-epigenetic reprogramming and resolves inflammatory injury Exposure to Bacterial CpG DNA Protects from Airway Allergic Inflammation by Expanding Regulatory Lung Interstitial Macrophages Two distinct interstitial macrophage populations coexist across tissues in specific subtissular niches Non-classical tissue monocytes and two functionally distinct populations of interstitial macrophages populate the mouse lung Inflammasomes: mechanism of action, role in disease, and therapeutics Adenovirus-delivered angiopoietin-1 ameliorates phosgene-induced acute lung injury via inhibition of NLRP3 inflammasome activation Long Noncoding RNAs Regulate Cell Growth, Proliferation, and Apoptosis Long Noncoding RNAs in Cardiovascular Pathology, Diagnosis, and Therapy. Circulation Mechanism of long non-coding RNA MALAT1 in lipopolysaccharide-induced acute kidney injury is mediated by the miR-146a/NF-κB signaling pathway Linagliptin Attenuates the Cardiac Dysfunction Associated With Experimental Sepsis in Mice With Pre-existing Type 2 Diabetes by Inhibiting NF-κB The long non-coding RNA MALAT1 is increased in renal ischemia-reperfusion injury and inhibits hypoxia-induced inflammation the expression of lncRNA MALAT1 Hypoxia-induced long non-coding RNA Malat1 is dispensable for renal ischemia/reperfusion-injury Circulating lncRNA NEAT1 correlates with increased risk, elevated severity and unfavorable prognosis in sepsis patients Long Non-Coding RNA Review and Implications in Lung Diseases Depression of lncRNA NEAT1 Antagonizes LPS-Evoked Acute Injury and Inflammatory Response in Alveolar Epithelial Cells via HMGB1-RAGE Signaling Long non-coding RNA CASC2 improved acute lung injury by regulating miR-144-3p/AQP1 axis to reduce lung epithelial cell apoptosis Down-regulation of lncRNA CASC9 aggravates sepsis-induced acute lung injury by regulating miR-195-5p/PDK4 axis LncRNA GAS5 suppresses inflammatory responses and apoptosis syndrome Long noncoding RNA FOXD3-AS1 regulates oxidative stress-induced apoptosis via sponging microRNA-150 Expression of long non-coding RNA NANCI in lung tissues of neonatal mice with hyperoxia-induced lung injury and its regulatory effect on NKX2 Protective effect of agmatine against hyperoxia-induced acute lung injury via regulating lncRNA gadd7 Long non-coding RNA SNHG16 promotes lipopolysaccharides-induced acute pneumonia in A549 cells via targeting miR-370-3p/IGF2 axis Long noncoding RNA SNHG16 targets miR-146a-5p/CCL5 to regulate LPS-induced WI-38 cell apoptosis and inflammation in acute pneumonia Down-regulation of long non-coding RNA SNHG14 miR-100/NF-κB axis Knockdown XIST alleviates LPS-induced WI-38 cell apoptosis and inflammation injury via targeting miR-370-3p/TLR4 in acute pneumonia Long non-coding RNA X-inactive specific transcript silencing ameliorates primary graft dysfunction following lung transplantation through microRNA-21-dependent mechanism Silence of MEG3 intensifies lipopolysaccharide-stimulated damage of human lung cells through modulating miR-4262 MEG3-4 is a miRNA decoy that regulates IL-1β abundance to initiate and then limit inflammation to prevent sepsis during lung infection Long non-coding RNA THRIL predicts increased acute respiratory distress syndrome risk and positively correlates with disease severity, inflammation, and mortality in sepsis patients Plasma long noncoding RNA IL-7R as a prognostic biomarker for clinical outcomes in patients with acute respiratory distress syndrome Flip the coin: IL-7 and IL-7R in health and disease Transcriptomic analysis of lung tissues after J o u r n a l P r e -p r o o f hUC-MSCs and FTY720 treatment of lipopolysaccharide-induced acute lung injury in mouse models Identification of long non-coding RNA and circular RNA in mice after intra-tracheal instillation with fine particulate matter LincRNA-p21 promotes mesenchymal stem cell migration capacity and survival through hypoxic preconditioning LncRNA analysis of lung tissues after hUC-MSCs and FTY720 treatment of lipopolysaccharide-induced acute lung injury in mouse models The roles of exosomal miRNAs and lncRNAs in lung diseases Long noncoding RNA NEAT 1 and its target microRNA-125a in sepsis: Correlation with acute respiratory distress syndrome risk, biochemical indexes, disease severity, and 28-day mortality Mesenchymal stem cells: mechanisms of potential therapeutic benefit in ARDS and sepsis Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START J o u r n a l P r e -p r o o f study): a randomised phase 2a safety trial COVID-19 therapy with mesenchymal stromal cells (MSC) and convalescent plasma must consider exosome involvement: Do the exosomes in convalescent plasma antagonize the weak immune antibodies? Long non-coding RNAs and pyroptosis Overexpression of MALAT1 Relates to Lung Injury through Sponging miR-425 and Promoting Cell Apoptosis during ARDS Long non-coding RNA MALAT1 exacerbates acute respiratory distress syndrome by upregulating ICAM-1 expression via microRNA-150-5p downregulation Knockdown of the lncRNA MALAT1 alleviates lipopolysaccharide-induced A549 cell injury by targeting the miR-17-5p/FOXA1 axis Negative feedback of NF-κB signaling by long noncoding RNA MALAT1 controls lipopolysaccharide-induced inflammation injury in human lung fibroblasts WI-38 Not applicable The study was supported in part by the National Natural Science Foundation of China The authors declare that they have no competing interests.